<DOC>
	<DOCNO>NCT01045460</DOCNO>
	<brief_summary>Patient Population : Patients active myeloma ( Stage II/III ) complete induction therapy eligible autologous stem cell transplant . Number Patients : Will treat total 32 evaluable patient 1:1 randomization aMILs v aMILs plus vaccine . An evaluable patient define one receive activate MILs least 6 month post-transplant . Study Objectives : Disease response determine Blade ' criterion primary endpoint trial one year . Additional study endpoint include progression free survival , parameter T cell reconstitution , anti-tumor immune response well effect osteoclastogenesis clonogenic myeloma precursor cell .</brief_summary>
	<brief_title>Trial Activated Marrow Infiltrating Lymphocytes Alone Conjunction With Allogeneic Granulocyte Macrophage Colony-stimulating Factor ( GM-CSF ) -Based Myeloma Cellular Vaccine Autologous Transplant Setting Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DurieSalmon Stage II III multiple myeloma Newly diagnose either prior receiving treatment complete induction therapy Relapsed myeloma previously transplant within past 5 year Measurable serum and/or urine Mprotein prior induction therapy document available . A positive serum free lite assay acceptable Age great 18 year old ECOG performance status 0 2 Meet institutional requirement autologous stem cell transplantation The patient must able comprehend sign informed consent Diagnosis follow plasma cell disorder : POEMS syndrome ( plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein [ Mprotein ] skin change ) Nonsecretory myeloma ( measurable protein Serum Free Lite Assay ) Plasma cell leukemia Amyloidosis Use corticosteroid ( glucocorticoid ) within 21 day pretransplant vaccine bone marrow collection Use myelomaspecific therapy lenalidomide within 21 day pretransplant vaccine In complete remission time bone marrow collection Infection require treatment antibiotic , antifungal , antiviral agent within seven day vaccination bone marrow collection Participation clinical trial , within four week prior vaccination bone marrow collection trial , involved investigational drug device History malignancy multiple myeloma within five year vaccination bone marrow collection , except adequately treat basal squamous cell skin cancer Active autoimmune disease ( e.g. , rheumatoid arthritis , multiple sclerosis , systemic lupus erythematosis ) require systemic treatment . Hypothyroidism without evidence Grave 's Disease Hashimoto 's thyroiditis permit Evidence spinal cord compression time transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Patients active myeloma ( Stage II/III ) complete induction therapy eligible autologous stem cell transplant</keyword>
</DOC>